Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2014

View Archived Issues

Potency of a novel NRTI against drug-resistant retroviruses

Phase III clinical data for DTaP5-IPV-Hib-HepB vaccine in infants

GW Pharmaceuticals provides new physician reports of Epidiolex

Capricor Therapeutics acquires rights to family of natriuretic peptides

DKFZ to evaluate Imaxio's pro-immunogenic technology in HPV vaccine

Johnson & Johnson reports on active third quarter 2014

NanoLogix configuring N-Assay Rapid diagnostic kits for viruses

Idera's IMO-9200 moves into phase I development

Compound derived from traditional Chinese medicine has antipsoriatic activity

Purdue Pharma patents novel Nav1.7 blockers for pain

New BUB1 inhibitors disclosed by Bayer Schering Pharma for cancer

Researchers at Aptose Biosciences patent new agents for cancer

Beta cell-specific insulin gene knockout model reveals pancreatic cell fate in diabetes

Actinobac Biomed receives second NIH grant to support development of Leukothera

Novel Nav1.7 blockers divulged by Genentech and Xenon Pharmaceuticals

Advaxis reports preliminary data from phase I/II trial of ADXS-HPV in anal cancer

ActoGeniX reports data from phase I study of AG-014

FDA approves two idiopathic pulmonary fibrosis drugs ahead of schedule

Hanmi Pharmaceuticals and Kinex Pharmaceuticals report data from phase I Oratecan study

Alexion submits NDA in Japan for asfotase alfa

Retrophin to divest non-core assets to Turing Pharmaceuticals

FDA clears Lyra Parainfluenza Assay for use

FDA issues refusal to file letter in response to Insys' NDA for dronabinol

FDA grants priority review for lenvatinib in thyroid cancer

Nivolumab and ipilimumab combination receives FDA orphan drug designation

Compstatin 40 given U.S. orphan drug status for paroxysmal nocturnal hemoglobinuria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...